Prevention of restenosis after PTCA by the requlation of Id, a trnscription factor of muscle differentiation.

通过调节 Id(肌肉分化的转录因子)来预防 PTCA 后的再狭窄。

基本信息

  • 批准号:
    06670716
  • 负责人:
  • 金额:
    $ 1.34万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)
  • 财政年份:
    1994
  • 资助国家:
    日本
  • 起止时间:
    1994 至 1995
  • 项目状态:
    已结题

项目摘要

We examined whether the phenotypic change of vascular smooth muscle cells (VSMC) were regulated by Id protein, a helix-loop-helix type transcription without basic region. Id mRNA expression in VSMC was examined by Northern analysis using rat Id cDNA probe. Id mRNA,which was not detected in rat aortic tissue, was markedly increased in cultured VSMC from bovine and human aorta in growing phase. When cells reached confluency, Id mRNA expression was significantly reduced to 22% of growing cells. Id mRNA expression in human direct coronary atherectomy samples was also examined using reverse transcription-polymerase chain reaction. Id mRNA was detected predominantly in samples from restenotic lesion after PTCA compared to primary atherosclerotic lesion (67% vs.25%, p<0.05). VSMC growth in 5% fetal bovine serum (FBS) measured by 3H-thymidine uptake and cell number were markedly decreased by the addition of antisense oligodeoxyribo-nucleotides (ODN) to Id (30 muM) (28% and 39%, respectively, p<0.01). However, chemotactic activity of VSMC assessed by micro Boyden chamber method using 5% FCS as a chemoattractant was not reduced by Id antisense ODN.These results suggest that Id expression is closely-related to phenotype change of VSMC from contraction to proliferation but not to chemotaxis, and may suggest that the change in VSMC phenotype is transcriptionally regulated by helix-loop-helix type trans-acting factors.
本实验研究了血管平滑肌细胞(VSMC)的表型变化是否受Id蛋白的调控。Id蛋白是一种螺旋-环-螺旋型的无碱基区的转录蛋白。以大鼠Id cDNA为探针,采用北方Northern杂交技术检测VSMC中Id mRNA的表达。IdmRNA在大鼠主动脉组织中未检测到,但在培养的牛和人主动脉VSMC生长期明显增加。当细胞达到汇合时,Id mRNA表达显著降低至生长细胞的22%。还使用逆转录-聚合酶链反应检测了人直接冠状动脉粥样硬化斑块切除术样本中Id mRNA的表达。Id mRNA在PTCA后再狭窄病变中的表达率明显高于原发性动脉粥样硬化病变(67% vs.25%,p<0.05)。在5%胎牛血清(FBS)中加入30 μ M的Id反义寡脱氧核苷酸(ODN)可显著降低VSMC的生长(分别为28%和39%,p<0.01)。结果表明,Id表达与VSMC从收缩到增殖的表型变化密切相关,而与VSMC的趋化性无关,提示VSMC表型变化受螺旋-环-螺旋型反式作用因子的转录调控。

项目成果

期刊论文数量(30)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Hoshida S et al: "Ebselen protects against ischemia/reperfusion injury in a canine model of myocardial infarction." Am J Physiol. 267. H2342-H2347 (1994)
Hoshida S 等人:“Ebselen 可预防犬类心肌梗塞模型中的缺血/再灌注损伤。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Kazuya T.et al.: "Polymorphonuclear lekocytes-induced injury in hyppoxic cardiac myocytes." Free Radical Biol Med. 17. 501-510 (1994)
Kazuya T.等人:“多形核白细胞诱导缺氧心肌细胞损伤。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hoshida S et al: "Gamma-glutamylcysteine ethyl ester for myocardial protection in dogs during ischemia and reperfusion." J Am Coll Cardiol. 24. 1391-1397 (1994)
Hoshida S 等人:“γ-谷氨酰半胱氨酸乙酯在狗缺血和再灌注期间具有心肌保护作用。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Yamashita N.,et al.: "Induction of manganese superoxid dismutase in rat cardiac myocytes increases tolerance to hypoxia 24 hours after preconditioning." J. Clin. Invest.94. 2193-2199 (1994)
Yamashita N. 等人:“大鼠心肌细胞中锰超氧化物歧化酶的诱导增强了预处理 24 小时后对缺氧的耐受性。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Hosida S,et al.: "Nitric oxide synthase protects the heart against ischemia-reperfusion injury in rabbits." J Pharmacol Exp Ther. 274. 413-418 (1995)
Hosida S 等人:“一氧化氮合酶可保护兔子心脏免受缺血再灌注损伤。”
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

HOSHIDA Shiro其他文献

HOSHIDA Shiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('HOSHIDA Shiro', 18)}}的其他基金

Infarct-Limiting Effect of gamma-glutamylcysteine Ethyl Ester in a Cnine Occlusion-Reperfusion Model
γ-谷氨酰半胱氨酸乙酯在犬闭塞再灌注模型中的梗死限制作用
  • 批准号:
    04670534
  • 财政年份:
    1992
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for General Scientific Research (C)

相似国自然基金

基于SIRT1靶点防治支架内再狭窄先导物的发现与机制研究
  • 批准号:
    81102444
  • 批准年份:
    2011
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Multi-tissue type condensations for trachea tissue regeneration via individual cell bioprinting
通过单细胞生物打印进行气管组织再生的多组织类型浓缩
  • 批准号:
    10643041
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Laryngotracheal Reconstruction with Engineered Cartilage
用工程软骨重建喉气管
  • 批准号:
    10660455
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Novel Bioresorbable Vascular Scaffolds with Uniform Biodegradation
具有均匀生物降解性的新型生物可吸收血管支架
  • 批准号:
    10930188
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Biocarpet: The Next Generation Endovascular Device for Peripheral Arterial Disease
Biocarpet:治疗外周动脉疾病的下一代血管内装置
  • 批准号:
    10744597
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Acoustic-anatomic modeling and development of a patient-specific wearable therapeutic ultrasound device for peripheral arterial disease
针对外周动脉疾病的患者专用可穿戴超声治疗设备的声学解剖建模和开发
  • 批准号:
    10603253
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Significance of endoscopic quantitative evaluation of small bowel stricture in patients with Crohn's disease and elucidation of restenosis factors after balloon dilatation
内镜定量评估克罗恩病患者小肠狭窄的意义及阐明球囊扩张后再狭窄因素
  • 批准号:
    23K07446
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Biodegradable Metal Stent Alloys for Vascular Applications
用于血管应用的可生物降解金属支架合金
  • 批准号:
    10643743
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Targeting smooth muscle cell BMAL1 as a new therapeutic strategy against restenosis
靶向平滑肌细胞 BMAL1 作为抗再狭窄的新治疗策略
  • 批准号:
    10561398
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Cyclin-dependent kinase (CDK)19-mediated vein graft intimal hyperplasia
细胞周期蛋白依赖性激酶(CDK)19介导的静脉移植内膜增生
  • 批准号:
    10664327
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
Software for stent failure prevention using intravascular OCT images
使用血管内 OCT 图像预防支架失效的软件
  • 批准号:
    10685081
  • 财政年份:
    2023
  • 资助金额:
    $ 1.34万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了